aap Implantate AG

Earnings Release • Jul 3, 2012

News Details

Ad-hoc | 3 July 2012 11:13

aap Implantate AG: aap preliminary report: strong H1 2012 growth (Sales: +33%); Further increase of sales forecast for the financial year 2012 to EUR 35.5 million

aap Implantate AG / Key word(s): Half Year Results/Forecast

03.07.2012 11:13

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc Announcement
in accordance with § 15 of the German Securities Trading Act (WpHG)

aap preliminary report: strong H1 2012 growth (Sales: +33%); Further
increase of sales forecast for the financial year 2012 to EUR 35.5 million

Berlin, July 3, 2012

Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a
global medical device company focused on innovative trauma products and
biomaterials for the orthopaedic market, achieved 33% sales growth in the
first half of the financial year 2012 with sales of EUR 18.8 million
(previous year: EUR 14.1 million). Compared with the previous year, sales
in the second quarter of 2012 rose by 17% to EUR 8.9 million from EUR 7.6
million. The first-half year-over-year growth was driven by higher product
sales (EUR +2.5 million) and a new exclusive license agreement (EUR +2.2
million) signed in March 2012. Based on the sales results for the first
three months of 2012, the Company anticipates first half 2012 EBITDA growth
to be more than 50% and first half 2012 EBIT growth to exceed 100% as
compared to the first half of 2011. The EBITDA in the second quarter of
2012 will not develop in the same way as the sales because of non-recurring
one time effects in the second quarter of 2011 amounting to EUR 0.4
million.

      2012 (in EUR million)    2011 (in EUR million)    Change

Sales
Q1 9.9 6.5 +51%
Q2e* 8.9 7.6 +17%
H1e* 18.8 14.1 +33%
EBITDA
Q1 2.1 0.8 >100%
Q2e* 1.1 - 1.4 1.3 -15% to +8%
H1e* 3.2 - 3.4 2.1 +52% to +62%

*expected figures for the respective period

Based on the strong results for the first an second quarter of 2012, the
Company is increasing its sales forecast to approximately EUR 35.5 million
for the financial year 2012, a corresponding growth of 22%. For the EBITDA
the management board expects an increase of more than 25% to approximately
EUR 5.2 million for the financial year 2012.

On the basis of, among other things, the current order intake, the
Management Board anticipates for the third-quarter 2012 sales of EUR 7.6
million to EUR 8.0 million, corresponding to sales growth of 10% to 16%.
For the first nine months of 2012, the Company expects sales growth of 26%
to 28%. For the first nine months of 2012, the Management Board expects
year-on-year EBITDA and EBIT growth of more than 40% and 100%,
respectively, as compared to the first nine months of 2011.

      2012e (in EUR million)    2011 (in EUR million)    Change

Sales
Q3 7.6 - 8.0 6.9 +10% to +16%
9m 26.4 - 26.8 21 +26% to +28%
EBITDA
Q3 0.9 - 1.2 0.8 +13% to +50%
9m 4.1 - 4.7 2.9 +41% to +62%

aap plans to publish its full Q2 2012 report on August 14, 2012.

This release contains forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. Many factors could cause the actual results, performance or
achievements of aap to be materially different from those that may be
expressed or implied by such statements. These factors include those
discussed in aap's public reports. Forward-looking statements therefore
speak only as of the date they are made. aap does not assume any obligation
to update the forward-looking statements contained in this release or to
conform them to future events or developments.

03.07.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---